Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Fasoracetam | Sabroxy (Oroxylum indicum) | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 20-100 mg 1-3 times daily (sublingual or oral) | — |
| Timing | Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food. | — |
| Cycle Duration | Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data. | — |
| Evidence Level | animal_plus_anecdotal | Emerging |
Non-classical racetam that modulates all three groups of metabotropic glutamate receptors (mGluR Groups I, II, and III) and upregulates GABA-B receptors — a unique mechanism that distinguishes it from other racetams. Also enhances high-affinity choline uptake (HACU) and stimulates acetylcholine release. Does not significantly affect adrenergic, serotonergic, or dopaminergic receptors. The GABA-B upregulation is particularly notable as it may counteract GABA-B receptor downregulation caused by phenibut or baclofen tolerance.
20-100 mg 1-3 times daily (sublingual or oral)
Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.
Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →